Background We previously reported a delayed phase of protection against infarction 24 hours after ischemic preconditioning in the rabbit. In the present study, we investigated the possibility that this "second window of protection," like the well-described early phase of protection in the rabbit, might be associated with adenosine receptor activation. Methods and Results In the first series of experiments, we examined whether adenosine receptor blockade with 8-(psulfophenyl)-theophylline (SPT) during preconditioning could abolish the delayed protection against infarction 24 hours later. Open-chest rabbits were subjected to myocardial preconditioning (PC) with the four 5-minute coronary occlusions or they were sham operated on (SHAM). During these procedures, animals received either SPT (PC+SPT, n=6; and SHAM+SPT, n=6) or vehicle (PC+VEH, n=12; and SHAM+VEH, n=11). Twenty-four hours later, infarct development after a 30-minute coronary occlusion/120-minute reperfusion insult was assessed with triphenyltetrazolium staining. In vehicle-treated rabbits, the infarct-to-risk ratio (I/R) was reduced from 53.6±5.7% (SHAM+VEH) to 32.9±4.6% (PC+VEH) (P<.05), clearly indicating a delayed phase of protection. Although I/R was not significantly different between SHAM+VEH (53.6±5.7%) and SHAM+SPT (61.7±5.4%), in PC+SPT the delayed protection was abolished (I/R=56.8-'-3.8%). In the second series of experiments, we examined if pharmacological adenosine A, receptor stimulation could evoke a delayed phase of protection. Conscious rabbits were pretreated with intravenous boluses of saline or the A, receptor-selective agonist 2-chloro-N6-cyclopentyladenosine (CCPA), and infarct size in response to 30-minute ischemia/120-minute reperfusion was assessed 24 hours later. I/R was 54.5±2.7% in saline-pretreated controls (n=12).
Pretreatment with 25 gg/kg CCPA (n=6), 50 gg/kg CCPA (n=6), or 100 ,ug/kg CCPA (n=6) resulted in I/R ratios of 37.1±4.2% (P<.01), 37 .7±2.2% (P<.01), and 26.3±5.7%
(P<.01), respectively. In both series of experiments, there were no differences in systemic hemodynamics during the infarct protocol, assessed as rate-pressure product, between the different experimental groups.
Conclusions Twenty-four hours after repetitive brief coronary occlusions, susceptibility to infarction in rabbit myocardium is reduced, an effect that may have clinical relevance. Results of the present study suggest that this second window of protection following preconditioning may, like the early phase of protection, be initiated by an adenosine-related mechanism.
(Circulation. 1994;90:2993-3000.)
Key Words * adenosine * myocardium * infarction T he marked myocardial protection associated with ischemic preconditioning is known to wane as the interval between the preconditioning coronary occlusions and the sustained occlusion is extended. For example, Murry et all showed that the infarctlimiting effect of preconditioning in canine myocardium was considerably reduced, although still marked, when the interval between the preconditioning stimulus and the prolonged ischemic insult was extended from 5 to 120 minutes. In rabbit myocardium, the waning of the protective effect may be even more rapid, such that the infarct-limiting effect is lost 120 minutes after preconditioning.2 This acutely manifested protection conferred by ischemic preconditioning is now widely recognized in the experimental literature. However, recent reports elicits a biphasic pattern of protection, ie, an acute phase of protection (the "classic" preconditioning effect) and a second, delayed phase of protection possibly arising as a consequence of a molecular adaptation to sublethal myocardial ischemia. Evidence for this "second window of protection" comes principally from two groups. We have observed a limitation of infarct size in rabbit myocardium 24 Adenosine Antagonist Study: Preparation Animals were prepared surgically (as described below). There were four experimental groups. The vehicle-treated groups received a 2 mL/kg dextrose-saline bolus before the first preconditioning coronary occlusion followed by infusion of 6 mL/kg over 1 to 2 hours. Group 1 was preconditioned and received dextrosesaline only (PC+VEH), and group 2 was sham-operated and received dextrose-saline only (SHAM+VEH).
The SPT groups received SPT dissolved in dextrose-saline (3.5 mg/mL). A loading dose of 7.5 mg/kg was given 5 to 6 minutes before the first coronary occlusion followed by a slow infusion of 20 mg/kg over 1 hour. Group 3 was preconditioned and received SPT (PC+SPT), and group 4 was sham-operated and received SPT (SHAM+SPT).
Animals in the antagonist study were anesthetized with a combination of 2 mg/kg diazepam IP and 0.3 mL/kg fentanyl citrate and fluanisone mixture IM (Hypnorm, Janssen Pharmaceuticals). of the ECG changes. The preconditioning protocol consisted of four 5-minute occlusions, each separated by 10-minute reperfusion. After preconditioning, the loose suture was left in situ, the thorax was evacuated, and the sternotomy was closed. Animals were extubated and allowed to recover from anesthesia with antibiotic cover (5 mg/kg enrofloxacin) and postoperative analgesia (30 gg/kg buprenorphine HCI).
Sham-operated animals underwent the same surgical procedure, including pericardiotomy, but as in our previous study3 no coronary artery suture was positioned.
A1 Receptor Agonist Study: Preparation
Conscious rabbits did not undergo surgery, but 24 hours before the infarction protocol they received intravenous bolus injections of saline solution (0.9% NaCl) or CCPA (25, 50, or 100 ,ug/kg administered in -1.5 mL saline) via a marginal ear vein. Animals were immediately returned to their pens with no further manipulation.
Infarction Procedure and Infarct Size Assessment
Approximately 24 hours after preparation (preconditioning or sham operation, CCPA or saline bolus), rabbits were anesthetized with a combination of 40 mg/kg pentobarbital sodium IV and 0.15 mL/kg Hypnorm IM. They were ventilated with 100% 02, and the right common carotid artery was cannulated for periodic hemodynamic and arterial blood gas measurements. Tidal volume was adjusted as necessary throughout the procedure to maintain arterial pH between 7.3 and 7.5 and Pco2 at <5.0 kPa. The thorax was reopened, and the coronary artery branch was identified. In the preconditioned groups, the in situ coronary ligature was used again. In all other groups, a ligature was positioned as described above.
After stabilization, 1000 IU heparin sodium was given intravenously before coronary occlusion. The artery was occluded for 30 minutes, followed by 120-minute reperfusion by manipulating the ligature and snare as described above.
At the end of 120-minute reperfusion, 1000 IU heparin sodium was administered before the heart was excised and Langendorff-perfused with saline solution to remove blood. The ligature was tightened again, and zinc-cadmium sulfide microspheres were infused through the aorta to delineate the myocardium at risk under ultraviolet light. After freezing at -18°C, the heart was sliced transversely from apex to base in 2-mm sections. The slices were defrosted, blotted, and incubated at 37°C with 1% w/v TTC in phosphate buffer (pH 7.4) for 10 to 20 minutes and fixed in 4% v/v formaldehyde solution to clearly distinguish between stained viable tissue and unstained necrotic tissue.9 The volumes of the infarcted tissue (I) and the tissue at risk (R) were determined by a computerized planimetric technique (Summa Sketch II, Summa Graphics).
Acute Hemodynamic Effects of CCPA
In a separate series of experiments, the short-term effects of 100 ug/kg CCPA on arterial blood pressure and heart rate were assessed in anesthetized rabbits. Rabbits were anesthetized with 40 mg/kg pentobarbital sodium IV and 0.15 mL/kg Hypnorm IM. They were ventilated, and the right carotid artery was cannulated for blood pressure and heart rate determination, as described above. CCPA (100 ,g/kg) or 0.9% saline was administered by intravenous bolus, as described above, and the hemodynamic effects were monitored continuously for 120 minutes.
Statistical Analysis
The data are presented throughout as mean±SEM values. 
Results

Exclusions
A total of 89 rabbits were used for these studies. Eighty-three were used for the adenosine antagonist study and the A1 receptor agonist study, and 6 were used for hemodynamic assessments after CCPA or saline administration. In the antagonist study, 7 rabbits were lost due to hemorrhage or respiratory failure during the preconditioning or sham operation protocol. In the A1 agonist study, no animals were lost after preliminary treatment with CCPA or saline. Thus, 76 animals survived the preparation protocols. During part 2, 3 animals were excluded due to severe VF during the infarct protocol (1 in PC+VEH, 1 in SHAM+VEH, 1 in saline-pretreated group); 3 were excluded due to hemorrhage or persistent tachycardia throughout the infarct protocol (2 in PC+VEH, 1 Values are mean±SEM. Baseline readings of blood pressure and heart rate were made during the 5-minute period before the 30-minute coronary artery occlusion. Rate-pressure product declined immediately after coronary occlusion and showed little recovery during the remainder of the protocol. Blood pressure was the main determinant of change in the rate-pressure product. There were no significant differences in rate-pressure product between the experimental groups at any time point.
the preconditioning protocol, the delayed protection was abolished (I/R, 56.8±3.8% in PC+SPT; P<.05 versus PC+VEH). The reduction in infarct size observed in the PC+VEH was not related to the volume of myocardium at risk during regional ischemia (R) since there were no significant differences in R between groups.
A1 Receptor Agonist Study Systemic Hemodynamic Changes During Infarct Protocol Table 3 summarizes changes in RPP during the infarction protocol in this second series of experiments. Twenty-four hours after CCPA or saline bolus, RPP was similar in all experimental groups. Although as in the antagonist study above blood pressure decreased during ischemia and reperfusion, the magnitude of this decline was similar in all groups, and there were no statistically significant differences in RPP between the groups at any time point. Infarct Limitation Hg) . This dose of CCPA, the highest used in the A1 receptor agonist study, caused a rapid reduction in heart rate. Maximal bradycardia (a reduction of 33.1±4.0% of baseline value) was observed 20 minutes after CCPA administration. By 90 minutes after the injection of CCPA, the magnitude of the bradycardia was not different than that seen in saline-treated controls, in which some bradycardia due to anesthesia was observed. The effect of 100 ,ug/kg CCPA on arterial pressure was more modest, with the peak hypotensive effect (a reduction in mean arterial pressure of 18.5 ± 7.7% of baseline value) observed 10 minutes after administration. Thirty minutes after the injection, arterial pressure was similar to that seen in the saline-treated controls. the results of this antagonist study, we could not preclude the possibility of some nonspecific, ie, not receptor related, effect of SPT on the myocardium that abolished or masked protection 24 hours later. Due to the sulfophenyl moeity, SPT does not cross the myocyte plasma membrane like some other xanthine derivatives,10 and therefore inhibition of cyclic AMP phosphodiesterases is not likely to account for the loss of protection.
In our second series of experiments, we were able to elicit myocardial protection against a lethal coronary occlusive insult by pretreatment 24 hours beforehand with three doses of the highly selective adenosine A1 receptor agonist CCPA. It is clear that all the animals in the infarct study were hemodynamically similar 24 hours after CCPA or saline treatment, and subtle differences in systemic hemodynamics during the infarct procedure are unlikely to account for the marked reductions in Baseline readings of blood pressure and heart rate were made during the 5-minute period before the 30-minute coronary artery occlusion. Rate-pressure product declined immediately after coronary occlusion and showed little recovery during the remainder of the protocol. Blood pressure was the main determinant of change in the rate-pressure product. There were no significant differences in rate-pressure product between the experimental groups at any time point. infarct size observed in either the ischemically preconditioned or CCPA-pretreated groups. Our hemodynamic observations with the highest dose of CCPA in anesthetized rabbits showed that a single bolus of 100 ,g/kg CCPA caused bradycardia over a period of -90 minutes. Because the drug was administered to uninstrumented conscious animals for the A, receptor agonist study, we have no data on the immediate hemodynamic effects of the CCPA bolus in these animals, although it is likely that in the conscious state the immediate hemodynamic effects are less pronounced than they are in the anesthetized state. We cannot exclude the possibility that CCPA could have evoked preconditioning of the heart indirectly through its hemodynamic effects. Although we believe it unlikely that the combined bradycardia and hypotension would be sufficient to diminish coronary perfusion so as to cause myocardial hypoxia, and therefore preconditioning, it is possible that a compensatory sympathetic activation occurred. Catecholamine release in response to the bradycardia might reasonably be expected, and this may explain the different time courses of the bradycardia and the hypotension after CCPA administration (see Fig 4) . There is some evidence that norepinephrine through an a1-adrenoreceptor effect can mimick, and may be the trigger for, the early preconditioning response in the rat."1 Although in the rabbit tyramineevoked catecholamine release induces protection against infarction,12 adrenoreceptor activation does not appear to be the primary mechanism of classic preconditioning protection in either the rabbit or the dog.13 Furthermore, it has been reported recently that norepinephrine administration to rats evokes myocardial protection in a biphasic manner,14 which may have some relevance to our present observations (see below). On the other hand, Thornton et al15 showed that adenosine A, receptor activation with R-phenylisopropyladenosine mimicked the early phase of preconditioning protection directly and not as a consequence of the bradycardia since cardiac pacing to overcome the bradycardia did not abolish the protection. Thus, although it is apparent in our study that adenosine receptor blockade during preconditioning abolished the delayed protection, at present we are not able to state conclusively that A1 receptor activation with CCPA directly triggers the delayed protection. The protection we have observed appears to be dependent on adenosine receptor activation, but further work is required to establish the contribution of factors other than A, receptor activation to this delayed protection.
Characterization and Potential of the Second Window of Protection
Although the degree of infarct reduction in the second window of protection is not as marked as that seen during the immediate phase of protection after ischemic preconditioning, this effect appears to be consistent and reproducible in the two laboratories where the protection has been observed.3.4 Thus, in our previous report we noted a decrease in I/R from 52.0% in sham-operated rabbits to 28.8% in preconditioned rabbits, a 45% reduction. In the present study, the reduction in I/R with ischemic preconditioning was similar at 39%. Kuzuya et a14 showed a reduction in I/R of 46% 24 hours after preconditioning in canine myocardium. In the present study, CCPA pretreatment in place of coronary occlusion led to reductions in I/R of between 31% and 52%.
The present study represents the third report of a delayed anti-infarct effect of preconditioning, but there also has been a negative study. Tanaka et al16 were unable to demonstrate a delayed phase of protection in the rabbit 24 hours after repeated brief coronary occlusions. The reasons for the failure in that study are not immediately apparent, but it may be that the lateral thoracotomy used in the negative study was more stressful than the median sternotomy used in the present study. In addition, lateral thoracotomy necessitates displacement of a lung to approach the heart. It is also possible that the gas used to ventilate the animals during preconditioning had some effect. In this and our previous study3 and the positive study of Kuzuya et al,4 100% 02 was administered. In contrast, Tanaka et al16 used air to ventilate. However, the possibility that 100% 02 was a major determinant of the subsequent myocardial protection seems remote, particularly in view of our present finding that CCPA administration to conscious, unventilated animals elicited a similar delayed protection.
So far, the duration of the second window of protection is unknown, but it is almost certainly longer than the 1 or 2 hours of opportunity that characterize the early period of protection after preconditioning. Be 
Possible Mechanisms for the Delayed Protection
The molecular basis of the protection we observed is unknown. It is well known that the rabbit is a species deficient in preformed collateral vessels,19 and it is most unlikely that angioneogenesis, providing collateral support to the ischemic zone, could occur within 24 hours in the preconditioned group. We believe it more probable that the myocardial protection is the direct result of enhanced cellular resistance to ischemia. Although the final mediators of this cellular resistance are unknown, we suggest that the long-term adaptation to the preconditioning stimulus may involve genetic modifications that lead to the appearance of cytoprotective substances in the myocardium. In this connection, we have been interested by recent work examining the role of protein kinase C (PKC) in the myocardial response to transient ischemia. Downey's group, 20 Banerjee's group,21 and our group22 have provided evidence that activation of PKC may be a crucial event in the mediation of classic preconditioning protection. In addition to translocation of the calcium-dependent a subtype and the calciumindependent S, 4, and E subtypes from the cytosol to the sarcolemma during brief periods of ischemia,23 it is possible that other subtypes may be translocated into the nucleus. This nuclear translocation may be a key event in the modification of gene-regulatory processes that could underlie the second window of protection. Because PKC translocation is proposed to occur after GTP regulatory protein (G protein) transduction, several receptor types, including the adenosine A, receptor, may influence PKC activity.
Many oncogenes and nuclear transcription factors may be activated by PKC (for review, see Reference 24 
